Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant HMGB2 protein is a laboratory-produced version of the High Mobility Group Box 2 (HMGB2) protein, a member of the high mobility group box family of non-histone chromosomal proteins. While intracellular HMGB2 plays a protective role in maintaining homeostasis by inhibiting the NLRP3 inflammasome and repressing IL-1 transcription, extracellular HMGB2 acts as a damage-associated molecular pattern (DAMP) that promotes inflammatory responses. Research indicates that extracellular HMGB2 levels increase in progressive atherosclerotic plaques following macrophage apoptosis. Recombinant HMGB2 protein has been shown to promote inflammation in vitro through the Receptor for Advanced Glycation End-products (RAGE) and exacerbate atherosclerosis in mouse models when administered intraperitoneally. This protein is primarily used as a research tool to investigate the role of HMGB2 in cardiovascular disease and inflammatory signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant HMGB2 protein.